Intangible Assets

OKYO appears to have limited intangible asset protection because its value proposition is still clinical-stage and not yet supported by approved products, which leaves little durable pricing power versus commercial biotech peers.

The company does not show evidence in the provided data of meaningful brand, patent-backed market exclusivity, or regulatory entrenchment that would materially improve retention versus peers.

Compared with established biotech peers that already monetize approved therapies, OKYO’s intangible assets are materially weaker because any future differentiation remains unproven in the market.

The absence of positive profitability and margin history in the provided metrics is consistent with a lack of monetized intangible assets that could sustain superior economics over 5–10 years.

Switching Costs

Switching costs are minimal because OKYO is not yet embedded in customer workflows or treatment protocols in a way that would make replacement costly versus peers with approved, standard-of-care products.

In clinical-stage development, physicians, payers, and patients can shift to alternative therapies or trial options with low friction, so retention advantages are not structurally established.

The provided metrics do not indicate recurring revenue, installed base economics, or contract lock-in, which are the main sources of durable switching costs in healthcare and biotech.

Relative to commercial peers with reimbursement coverage and prescribing inertia, OKYO has far weaker customer stickiness and therefore much lower moat durability.

Network Effects

OKYO does not appear to benefit from network effects because drug development and commercialization do not create self-reinforcing user growth in the way platform businesses do.

There is no evidence in the provided data of data-network accumulation, ecosystem lock-in, or multi-sided adoption that would compound advantage versus peers.

Compared with peers that may leverage large real-world evidence bases, broad prescriber familiarity, or distribution reach, OKYO lacks a visible feedback loop that strengthens over time.

Without approved products or a scaled user base, any future network-like benefit remains speculative and cannot support current moat durability.

Cost Advantage

OKYO shows no evidence of a structural cost advantage because the provided metrics indicate negative ROIC and no operating efficiency that would translate into lower unit economics versus peers.

Clinical-stage biotech companies typically face high R&D intensity and limited scale economies, so OKYO is unlikely to outperform larger peers on cost structure at this stage.

The absence of positive asset turnover and the extreme negative cash conversion cycle in the provided data do not support a claim of superior operating efficiency.

Relative to larger diversified biopharma peers, OKYO lacks procurement, manufacturing, or commercialization scale that would sustainably lower costs and widen margins.

Efficient Scale

OKYO does not appear to benefit from efficient scale because the market for its current assets is not shown to be concentrated in a way that would limit room for multiple competitors.

The company is too early in development to demonstrate that fixed-cost absorption or regulatory barriers create a durable scale moat versus peers.

Unlike large incumbents that can spread R&D, manufacturing, and commercialization costs across broad portfolios, OKYO has not shown scale-based operating leverage in the provided metrics.

The negative profitability profile suggests that any scale benefits are not yet sufficient to create a durable cost or margin advantage over peers.

Overall Score

OKYO’s moat is weak versus peers because the provided evidence shows a clinical-stage company with no demonstrated switching costs, network effects, cost advantage, or efficient scale, and only limited unproven intangible assets.